Litcius/Paper detail

Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)

Finn Mildner, Sieghart Sopper, Arno Amann, Andreas Pircher, Georg Pall, Stefan Köck, Erin Naismith, Dominik Wolf‎, Gabriele Gamerith

2020Critical Reviews in Oncology/Hematology31 citationsDOIOpen Access PDF

Abstract

T-cells connect to a favorable outcome. Circulating tumor cells expressing PD-L1 were mainly associated with poor overall survival and treatment failure. CONCLUSION: Measurement of immunological factors as liquid biomarkers is feasible and has shown promising results. The use of coherent nomenclatures, cross-platform assay comparisons and validations through appropriate powered clinical trials are urgently required to push this auspicious field.

Topics & Concepts

ImmunotherapyBiomarkerLung cancerMedicineCD8Clinical trialOncologyCancerCancer immunotherapyInternal medicineCancer researchImmune systemImmunologyBiologyBiochemistryCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsImmunotherapy and Immune Responses
Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC) | Litcius